Evercore ISI initiated coverage of Immunome (IMNM) with an Outperform rating and $18 price target The company is developing a deep ADC pipeline that should emerge as the primary driver of long-term value, but the nearer-term focus is on varegacestat ahead of Phase 3 desmoid tumor data that the firm expects late in the year, the analyst tells investors. The firm is “confident in a positive outcome,” seeing 70% odds of success, and says physician feedback suggests that data only need to be comparable to the Ogsiveo standard of care to gain share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome’s Promising Pipeline and Financial Stability Justify Buy Rating
- Immunome Advances Cancer Therapy Pipeline Amid Financial Loss
- Promising Outlook for Immunome’s Varegacestat: Buy Rating Affirmed
- Immunome’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating
- Immunome reports Q2 EPS (50c), consensus (50c)